The President Talks Prescription Drugs
This article was originally published in RPM Report
President Obama hosted a “town hall” discussion on health care reform and senior citizens June 8. Not surprisingly, the plan to fill in the Medicare Part D donut hole was touched on several times. If manufacturers expected credit for giving a 50% discount, they didn’t get it. They did, however, hear some unwelcome discussion of ideas like price negotiation. On the other hand, the President stressed the role of health care reform in assuring access to drugs. Excerpts from the official White House transcript.
You may also be interested in...
A Kaiser Family Foundation report on the impact of the Medicare Part D donut hole reads like an artifact of history. But it helps quantify the benefit to brand name industry from closing the donut hole in the context of health care reform.
US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.
Whether CME for pain management has the intended impact on prescribing is likely focus of new ‘suite of studies’ intended to assess the opioid REMS program. The challenges for FDA include teasing out the impact of the risk management program amid all the other public health efforts on opioids.